Posted by Michael Wonder on 02 Aug 2021
UCB’s bimekizumab issued NICE recommendation for severe plaque psoriasis
2 August 2021 - NICE has issued a Final Appraisal Determination recommending UCB’s bimekizumab as an option for the treatment of adults with severe plaque psoriasis.
This recommendation is the first to follow NICE’s new Expedited Low Risk Fast Track Appraisal process, a pathway developed in response to the COVID-19 pandemic to minimise delaying access to new innovative medicines.
